Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $12.9 million.

  • Heron Therapeutics' Cost of Revenue rose 1795.48% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.9 million, marking a year-over-year decrease of 97.4%. This contributed to the annual value of $47.1 million for FY2024, which is 3039.19% down from last year.
  • As of Q3 2025, Heron Therapeutics' Cost of Revenue stood at $12.9 million, which was up 1795.48% from $11.6 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Cost of Revenue peaked at $25.2 million during Q3 2021, and registered a low of $11.0 million during Q3 2024.
  • For the 5-year period, Heron Therapeutics' Cost of Revenue averaged around $17.2 million, with its median value being $17.8 million (2022).
  • As far as peak fluctuations go, Heron Therapeutics' Cost of Revenue soared by 10140.63% in 2021, and later crashed by 4591.09% in 2024.
  • Over the past 5 years, Heron Therapeutics' Cost of Revenue (Quarter) stood at $24.5 million in 2021, then dropped by 27.41% to $17.8 million in 2022, then crashed by 30.64% to $12.3 million in 2023, then dropped by 10.31% to $11.1 million in 2024, then rose by 17.05% to $12.9 million in 2025.
  • Its Cost of Revenue stands at $12.9 million for Q3 2025, versus $11.6 million for Q2 2025 and $12.3 million for Q1 2025.